FRIDAY, Aug. 10 (HealthDay News) -- Lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration to treat diabetic macular edema (DME), an eye condition that could threaten a diabetic person's sight, the agency said Friday in a news release.
The condition occurs when fluid leaks into the macula, the center of the eye's retina. This leads to macular swelling, causing blurred vision.
Diabetes is the leading cause of new cases of blindness among people aged 20 to 74, the FDA said, citing statistics from the U.S. Centers for Disease Control and Prevention.
Commonly reported side effects of Lucentis include bleeding of the eye's conjunctiva tissue, eye pain, floaters and increased pressure inside the eye.
Lucentis, marketed by San Francisco-based Genentech, was approved previously for wet age-related macular degeneration, and another form of macular edema.
The U.S. National Eye Institute has more about diabetic eye disease.
diabetes and blood sugar help
These simple steps may be all it takes to stay healthy and stop worrying about sugar problems.
U.S. News evaluated 25 of the most popular diets and identified the best.
Understanding how insulin affects your blood sugar can help you better manage your condition.
How much sugar is too much, and simple ways to eat less added sugar.
Give your body a good once-over to see if trouble may be lurking.
These aspects of your office may be dangerous to your health.
The year's top health headlines, from federal health policy to celebrity controversy.
Try these expert tips on how to deal with your biggest sexual roadblocks and boost your pleasure in the bedroom tonight.